Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
104.39
+5.75 (5.83%)
At close: Nov 7, 2025, 4:00 PM EST
102.31
-2.08 (-1.99%)
After-hours: Nov 7, 2025, 7:10 PM EST
Cidara Therapeutics Revenue
In the year 2024, Cidara Therapeutics had annual revenue of $1.28M, down -94.52%.
Revenue (ttm)
$1.28M
Revenue Growth
-94.52%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
2.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.28M | -22.01M | -94.52% |
| Dec 31, 2023 | 23.28M | -213.00K | -0.91% |
| Dec 31, 2022 | 23.50M | -26.08M | -52.60% |
| Dec 31, 2021 | 49.57M | 37.51M | 310.81% |
| Dec 31, 2020 | 12.07M | -8.85M | -42.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CDTX News
- 16 hours ago - Cidara Therapeutics, Inc. (CDTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 11 days ago - Cidara Therapeutics to Participate in November Investor Conferences - GlobeNewsWire
- 15 days ago - Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025 - GlobeNewsWire
- 16 days ago - Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025 - GlobeNewsWire
- 17 days ago - Cidara Therapeutics: A Potential Blockbuster In Flu Prevention - Seeking Alpha
- 18 days ago - Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025 - GlobeNewsWire
- 26 days ago - Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 - GlobeNewsWire